HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 44 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $1,033,000 | – | 285,478 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Novo Holdings A/S | 1,280,185 | $9,755,000 | 1.01% |
| Cormorant Asset Management, LP | 201,000 | $1,532,000 | 0.24% |
| PUTNAM INVESTMENTS LLC | 575,692 | $4,386,000 | 0.01% |
| Alyeska Investment Group, L.P. | 114,113 | $870,000 | 0.01% |
| VANGUARD GROUP INC | 4,355,424 | $131,473,000 | 0.01% |
| BLACKROCK ADVISORS LLC | 463,200 | $3,530,000 | 0.00% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 26,100 | $199,000,000 | 0.00% |
| Ironwood Financial, llc | 870 | $7,000 | 0.00% |
| PANAGORA ASSET MANAGEMENT INC | 24,293 | $185,000 | 0.00% |
| Sonora Investment Management, LLC | 500 | $3,000 | 0.00% |